Bayer introduces medication for chronic kidney disease
PTI, Aug 26, 2022, 11:38 AM IST
Credit: iStock Photo
Drugmaker Bayer on Thursday said it has introduced a medication for the treatment of chronic kidney disease associated with diabetes under the brand name Kerendia.
The drug is a non-steroidal, selective mineralocorticoid receptor antagonist indicated for patients with chronic kidney disease associated with type 2 diabetes.
“The major focus of therapy in patients with chronic kidney disease and diabetes is to prevent end-stage renal disease or kidney failure. Despite therapy, these patients often progress to kidney failure.
“Finerenone (Kerendia) therefore offers a new treatment approach for these vulnerable patients to slow down the progression of chronic kidney disease and reduce the risk of kidney failure,” Bayer Zydus Pharma Managing Director Manoj Saxena said in a statement.
Diabetes is the leading cause of chronic kidney disease and end-stage kidney disease in India.
Around seventy-four million people suffer from diabetes in the country and this figure is likely to increase to ninety-three million by 2030.
The number of people with diabetes in India is the second highest in the world, after China.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
Drinking tea, coffee linked to lower risk of head and neck cancer: Study
Study shows how brain chemicals control eating, could help develop improved obesity drugs
‘Faster walkers’ had significantly lower risk of diabetes, hypertension: Study
World Meditation Day 2024: Celebrating inner peace and well-being
Virus causing gut infections could play role in development of Alzheimer’s: Study
MUST WATCH
Latest Additions
Thanks for visiting Udayavani
You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.